Scaling Clinical Genomics at PMWC 2015

PMWCLogo2015

Now in its sixth year, the Personalized Medicine World Conference (PMWC) Silicon Valley has grown into a must-attend event for anyone interested in keeping up with this fast-paced field.  This year’s meeting is particularly timely, falling just a week after President Obama announced his federal Precision Medicine initiative.

Sean Scott

Sean Scott, QIAGEN Bioinformatics’ Vice President and General Manager of Clinical Genomics

PMWC 2015 is expected to bring together more than 1,000 professionals who will hear presentations from 100+ speakers on topics ranging from prenatal diagnostics and cancer genomics to crowdsourcing and reimbursement.  Sean Scott, QIAGEN Bioinformatics’ Vice President and General Manager of Clinical Genomics will be among this year’s speakers and will take the stage on Wednesday, January 28 at 11:15 AM.

A common theme running across many of the talks and sessions at this year’s PMWC, is the application of genomic data in clinical settings.  As labs migrate from single-gene Sanger sequencing tests to multi-gene panels and exome or whole genome next-generation sequencing (NGS)-based tests, labs are inevitably going to encounter increased complexities in tests, phenotypes, and variants that will constrain their ability to effectively interpret and report out on findings.

In his talk, Sean will discuss the new QIAGEN Clinical Decision Support platform, powered by Ingenuity. This new platform, set to launch commercially later this year, was built for molecular diagnostics and molecular pathology testing laboratories who want to scale their clinical NGS-based testing solutions and accelerate data interpretation with useful reports for clinically relevant and actionable variants.  With a fully integrated, web-based workflow, this platform will greatly reduce the average amount of time it takes a lab to classify variants, as well as, increase confidence in the clinical assessment of the observed variant. Next-generation sequencing has tremendous potential in the clinical environment; however, the market for NGS-based clinical testing will not develop quickly unless labs can streamline and scale their test interpretation and reporting workflow from variant annotation through scoring, classification, and reporting.

If you are attending this year’s meeting, in addition to hearing Sean’s talk you can stop by our Booth #10 where the QIAGEN team can answer any questions you may have about the Clinical Decision Support platform or any of the other QIAGEN Bioinformatics products.